Private Trust Company’s Haemonetics HAE Stock Holding History

Private Trust Company’s Portfolio HAE Stock Details HAE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-150	Closed	-$8.45K	–	2740
2026 Q1	$8.45K	Buy	+150	New	+$9.77K	﹤0.01%	2028

Other funds holding HAE

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Private Trust Company's HAE Position: Q2 2026 in Review

Private Trust Company sold out of Haemonetics (HAE) in Q2 2026, closing a stake of 150 shares — an estimated $8.45K sold.

Private Trust Company first reported a position in HAE in Q1 2026 and held it in 1 quarter. The position peaked at $8.45K in Q1 2026. 329 funds tracked by Wall St. Rank hold HAE as of Q2 2026.

Private Trust Company reported no remaining Haemonetics position as of Q2 2026 after selling out during the quarter.
Private Trust Company sold 150 Haemonetics shares in Q2 2026, an estimated $8.45K.
Private Trust Company first reported a position in Haemonetics in Q1 2026 and held it in 1 quarter.
Private Trust Company's Haemonetics position peaked at $8.45K in Q1 2026.
329 funds tracked by Wall St. Rank held Haemonetics as of Q2 2026.

Based on Private Trust Company's 13F filing for Q2 2026, filed 28 Jul 2026.